INT29556

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1986
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 26
Total Number 29
Disease Relevance 9.08
Pain Relevance 6.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
spinal cord 1
keratinocyte 1
reticulum 1
CALM1 (Homo sapiens)
Pain Link Frequency Relevance Heat
complementary and alternative medicine 380 100.00 Very High Very High Very High
antagonist 144 100.00 Very High Very High Very High
Kinase C 28 99.92 Very High Very High Very High
qutenza 162 99.12 Very High Very High Very High
Lasting pain 32 99.04 Very High Very High Very High
Spinal cord 13 97.96 Very High Very High Very High
Pain 192 96.18 Very High Very High Very High
drug abuse 173 95.40 Very High Very High Very High
cocaine 89 92.60 High High
cannabis 48 92.24 High High
Disease Link Frequency Relevance Heat
Pain 210 99.04 Very High Very High Very High
Psychosis 18 99.02 Very High Very High Very High
Bullous Skin Disease 608 98.68 Very High Very High Very High
Diabetes Mellitus 243 98.60 Very High Very High Very High
Spinal Cord Injury 1 97.96 Very High Very High Very High
Acantholysis 130 97.88 Very High Very High Very High
Drug Dependence 179 95.40 Very High Very High Very High
Toxicity 9 95.04 Very High Very High Very High
Pancreatic Cancer 48 93.48 High High
Inflammatory Pain 30 90.16 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
There was a rough correlation between the ability to elevate intracellular Ca2+ and potencies for inhibition of calmodulin.
Negative_regulation (inhibition) of calmodulin
1) Confidence 0.57 Published 1995 Journal Eur. J. Pharmacol. Section Abstract Doc Link 7774682 Disease Relevance 0 Pain Relevance 0.28
In loperamide-pretreated BBMVs, calmodulin activity was significantly decreased (12 +/- 2 vs. 38 +/- 4 pmol/mg protein).
Negative_regulation (decreased) of calmodulin
2) Confidence 0.57 Published 1988 Journal Gastroenterology Section Abstract Doc Link 2836258 Disease Relevance 0 Pain Relevance 0.06
CAM may be defined differently in other research, especially since CAM is, by its nature, somewhat dynamic and evolving.
Negative_regulation (defined) of CAM associated with complementary and alternative medicine
3) Confidence 0.37 Published 2008 Journal BMC Complement Altern Med Section Body Doc Link PMC2394513 Disease Relevance 0 Pain Relevance 0.43
First, we selected a broad definition of CAM based on our available survey data.
Negative_regulation (definition) of CAM associated with complementary and alternative medicine
4) Confidence 0.37 Published 2008 Journal BMC Complement Altern Med Section Body Doc Link PMC2394513 Disease Relevance 0 Pain Relevance 0.45
The third section of the survey, based on a review of Taiwanese and English language literature, focused on patterns of CAM use including: the reasons for CAM use, factors influencing the decision to use CAM, the administration of CAM with conventional treatments, the disclosure of CAM use to healthcare professionals, and the reasons for not using CAM or ceasing CAM.
Negative_regulation (disclosure) of CAM
5) Confidence 0.37 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2952338 Disease Relevance 0.16 Pain Relevance 0
The third section of the survey, based on a review of Taiwanese and English language literature, focused on patterns of CAM use including: the reasons for CAM use, factors influencing the decision to use CAM, the administration of CAM with conventional treatments, the disclosure of CAM use to healthcare professionals, and the reasons for not using CAM or ceasing CAM.
Negative_regulation (administration) of CAM
6) Confidence 0.37 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2952338 Disease Relevance 0.16 Pain Relevance 0
Prevalence and Patterns of Change of CAM Use before and after Diagnosis of Type 2 Diabetes
Negative_regulation (Prevalence) of CAM associated with diabetes mellitus
7) Confidence 0.37 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2952338 Disease Relevance 0.42 Pain Relevance 0
The prevalence of CAM use was 22.7% before and 61.0% after diagnosis with Type 2 diabetes with nutritional supplements being the most commonly used CAM before and after diagnosis.
Negative_regulation (prevalence) of CAM associated with diabetes mellitus
8) Confidence 0.37 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Abstract Doc Link PMC2952338 Disease Relevance 0.54 Pain Relevance 0
Finally, it is pertinent to highlight Willis and White's sociological analysis of the implications of the EBM theory for the future development of CAM.
Negative_regulation (development) of CAM associated with complementary and alternative medicine
9) Confidence 0.36 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2952302 Disease Relevance 0 Pain Relevance 0.43
The significant decrease in CALM1, CALM2 and CAMKIIB transcripts suggest that altered regulation of neuroplasticity and dendritic architecture by calmodulin-regulated pathways could be a common theme in human abuse of cocaine, cannabis and/or phencyclidine.


Negative_regulation (decrease) of CALM1 associated with cannabis and cocaine
10) Confidence 0.30 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762434 Disease Relevance 0.14 Pain Relevance 0.16
Our findings are also similar to the prevalence of CAM use in a population of chronic pain patients with spinal cord injuries who reported 40.3% used these alternative treatments in the past year [20].
Negative_regulation (prevalence) of CAM in spinal cord associated with complementary and alternative medicine, lasting pain and spinal cord
11) Confidence 0.27 Published 2007 Journal BMC Complement Altern Med Section Body Doc Link PMC1885447 Disease Relevance 0.39 Pain Relevance 0.71
The inhibitor W7, which blocks calcium/calmodulin, prevented the PEF-stimulated increase in both nitric oxide and cGMP.
Negative_regulation (blocks) of calmodulin
12) Confidence 0.20 Published 2008 Journal J. Orthop. Res. Section Abstract Doc Link 18240331 Disease Relevance 0.13 Pain Relevance 0.06
34), representing a number of consistently changed functional classes: Calmodulin-related transcripts (CALM1, CALM2, CAMK2B) were decreased, while transcripts related to cholesterol biosynthesis and trafficking (FDFT1, APOL2, SCARB1), and Golgi/endoplasmic reticulum (ER) functions (SEMA3B, GCC1) were all increased.
Negative_regulation (re decrea) of CALM1 in reticulum
13) Confidence 0.18 Published 2006 Journal PLoS ONE Section Abstract Doc Link PMC1762434 Disease Relevance 0.76 Pain Relevance 0.42
CPZ and N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide (W-7) can also block calcium-dependent activation processes by inhibition of calmodulin and protein kinase C.
Negative_regulation (inhibition) of calmodulin associated with kinase c
14) Confidence 0.17 Published 1986 Journal Transplantation Section Abstract Doc Link 3097893 Disease Relevance 0 Pain Relevance 0.22
Although structurally distinct, both calmidazolium and W-7 are considered selective and potent inhibitors of calmodulin, yet they act extremely differently on the TRPV1 target, which is an important issue in future drug discovery.
Negative_regulation (inhibitors) of calmodulin
15) Confidence 0.15 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1890308 Disease Relevance 0.19 Pain Relevance 0.39
An additional 113 transcripts were significantly changed in Groups I–II only; 44 transcripts, including FIBP, VTN, STOM, ICAM1, SEMA3B, RARG, RARA, were increased, and 68 transcripts, including APOL1, CALM1, CALM2, CAMK2B, GNB2L1, HINT1, RAB9A, CHEK1, PPP2CA and NFKBIA, were decreased.
Negative_regulation (decreased) of CALM1
16) Confidence 0.13 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762434 Disease Relevance 0.18 Pain Relevance 0.15
Our new data, in lieu of expectations, suggest that bona fide calmodulin antagonists blocks and do not promote Ca2+-transport via TRPV1.
Negative_regulation (blocks) of calmodulin associated with antagonist
17) Confidence 0.11 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1890308 Disease Relevance 0.18 Pain Relevance 0.29
To test this hypothesis and better understand channel function of TRPV1, we carried out experiments with tricyclic anti-psychotic calmodulin antagonist drugs and other selective inhibitors of calmodulin.
Negative_regulation (inhibitors) of calmodulin associated with psychosis and antagonist
18) Confidence 0.11 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1890308 Disease Relevance 0.23 Pain Relevance 0.28
Likewise conventional calmodulin inhibitors, camstatin inhibited capsaicin -induced Ca2+-transport (IC50?
Negative_regulation (inhibitors) of calmodulin associated with qutenza
19) Confidence 0.11 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1890308 Disease Relevance 0 Pain Relevance 0.48
Camstatin, a selective peptide blocker of calmodulin, inhibits vanilloid-induced Ca2+-uptake in intact TRPV1+ cells, and suggests an extracellular site of inhibition.
Negative_regulation (blocker) of calmodulin
20) Confidence 0.11 Published 2007 Journal PLoS ONE Section Abstract Doc Link PMC1890308 Disease Relevance 0.49 Pain Relevance 0.41

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox